Skip to main content
. 2022 Mar 1;13:848387. doi: 10.3389/fimmu.2022.848387

Figure 3.

Figure 3

Forest plot of the subgroup analyses for overall survival. HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; TACE, transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; TACE-L-P, transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor; TACE-L, transarterial chemoembolization combined with lenvatinib.